These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 31721165)

  • 21. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
    J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
    Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
    Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications.
    Ala M; Mohammad Jafari R; Dehpour AR
    Fundam Clin Pharmacol; 2021 Apr; 35(2):235-259. PubMed ID: 33226665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
    Bacconi L; Gressier F
    Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
    Ioakeimidis N; Kostis JB
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
    Kukreja RC
    Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P; Sander GE; Giles TD
    Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
    [No Abstract]   [Full Text] [Related]  

  • 38. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
    Rosen RC; Kostis JB
    Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sex, erectile dysfunction, and the heart: a growing problem].
    Görge G; Flüchter S; Kirstein M; Kunz T
    Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.